Quick Answer
Opus Genetics, Inc. reported Total Revenue of $14.20 million for fiscal year 2025.
Opus Genetics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $14.20M +29.1% |
$10.99M -42.3% |
$19.05M -52.2% |
$39.85M +6665.7% |
$589.0K | $0.00 |
| Revenue (ASC 606) | $14.20M +29.1% |
$10.99M -42.3% |
$19.05M -52.2% |
$39.85M +6665.7% |
$589.0K | $0.00 |
| Net Income | -$49.59M +13.8% |
-$57.53M -476.1% |
-$9.99M -155.8% |
$17.89M +131.6% |
-$56.69M -130.3% |
-$24.62M -299.1% |
| Diluted EPS | -$0.80 +62.8% |
-$2.15 -367.4% |
-$0.46 -152.9% |
$0.87 +122.8% |
-$3.82 +27.7% |
-$5.28 |
| Total Assets | $50.24M +36.3% |
$36.86M -31.7% |
$53.95M +10.1% |
$48.99M +87.9% |
$26.08M +47.5% |
$17.68M +891.1% |
| Cash and Equivalents | $45.09M +48.7% |
$30.32M -40.0% |
$50.50M +18.5% |
$42.63M +73.8% |
$24.53M | — |
| Long-Term Debt | $1.13M | $0.00 | — | — | — | — |
| Stockholders Equity | $15.35M +128.3% |
$6.72M -86.5% |
$49.91M +7.9% |
$46.24M +108.1% |
$22.22M +265.0% |
-$13.47M -78.1% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$38.60M +37.8% |
-$62.07M -487.7% |
-$10.56M -158.0% |
$18.23M +180.3% |
-$22.70M -13.7% |
-$19.97M -376.2% |
| Shares Outstanding | 69.89M +121.4% |
31.57M +31.7% |
23.98M +14.9% |
20.86M +10.7% |
18.85M +73.2% |
10.88M +281.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.08M | -20.4% | +6.8% |
| Revenue (ASC 606) | September 30, 2025 | $3.08M | -20.4% | +6.8% |
| Net Income | September 30, 2025 | -$17.45M | -131.9% | -135.2% |
| Diluted EPS | September 30, 2025 | -$0.25 | +13.8% | -108.3% |
| Total Assets | September 30, 2025 | $36.12M | -10.6% | -6.6% |
| Cash and Equivalents | September 30, 2025 | $30.82M | -15.9% | -5.0% |
| Long-Term Debt | September 30, 2025 | $1.07M | — | +6.8% |
| Stockholders Equity | September 30, 2025 | $5.97M | -82.6% | -65.9% |
| R&D Expense | September 30, 2020 | $149.6K | -86.8% | -35.4% |
| Operating Income | September 30, 2025 | -$8.31M | -3.8% | +6.7% |
| Shares Outstanding | September 30, 2025 | 64.54M | +146.4% | +7.7% |
- Opus Genetics, Inc. reported Total Revenue of $14.20 million for fiscal year 2025.
- Opus Genetics, Inc. showed an increase of +29.1% in Total Revenue compared to the prior fiscal year.
- Opus Genetics, Inc. reported Revenue (ASC 606) of $14.20 million for fiscal year 2025.
- Opus Genetics, Inc. showed an increase of +29.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Opus Genetics, Inc. reported Net Income of -$49.59 million for fiscal year 2025.
- Opus Genetics, Inc. showed an increase of +13.8% in Net Income compared to the prior fiscal year.
- Opus Genetics, Inc. reported Diluted EPS of $0.80 per share (loss) for fiscal year 2025.
- Opus Genetics, Inc. showed an increase of +62.8% in Diluted EPS compared to the prior fiscal year.
- Opus Genetics, Inc. reported Total Assets of $50.24 million for fiscal year 2025.
- Opus Genetics, Inc. showed an increase of +36.3% in Total Assets compared to the prior fiscal year.
- Opus Genetics, Inc. reported Cash and Equivalents of $45.09 million for fiscal year 2025.
- Opus Genetics, Inc. showed an increase of +48.7% in Cash and Equivalents compared to the prior fiscal year.
- Opus Genetics, Inc. reported Long-Term Debt of $1.13 million for fiscal year 2025.
- Opus Genetics, Inc. reported Stockholders Equity of $15.35 million for fiscal year 2025.
- Opus Genetics, Inc. showed an increase of +128.3% in Stockholders Equity compared to the prior fiscal year.
- Opus Genetics, Inc. reported R&D Expense of $5.48 million for fiscal year 2019.
- Opus Genetics, Inc. showed a decrease of -58.2% in R&D Expense compared to the prior fiscal year.
- Opus Genetics, Inc. reported Operating Income of -$38.60 million for fiscal year 2025.
- Opus Genetics, Inc. showed an increase of +37.8% in Operating Income compared to the prior fiscal year.
- Opus Genetics, Inc. reported Shares Outstanding of 69.89 million shares for fiscal year 2025.
- Opus Genetics, Inc. showed an increase of +121.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: